NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Short Interest Up 92.7% in January

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totaling 3,527,843 shares, a growth of 92.7% from the December 31st total of 1,831,090 shares. Currently, 14.7% of the company’s stock are sold short. Based on an average daily volume of 2,710,433 shares, the short-interest ratio is currently 1.3 days. Based on an average daily volume of 2,710,433 shares, the short-interest ratio is currently 1.3 days. Currently, 14.7% of the company’s stock are sold short.

Institutional Trading of NRx Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Ethos Financial Group LLC purchased a new position in shares of NRx Pharmaceuticals in the 3rd quarter worth approximately $39,000. Sjbenen Advisory LLC acquired a new position in NRx Pharmaceuticals in the 4th quarter worth approximately $41,000. One Wealth Management Investment & Advisory Services LLC increased its stake in shares of NRx Pharmaceuticals by 86.1% in the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock worth $92,000 after acquiring an additional 12,950 shares during the period. Two Sigma Investments LP boosted its stake in shares of NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after buying an additional 20,880 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in NRx Pharmaceuticals by 27.9% in the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after purchasing an additional 37,598 shares in the last quarter. Institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Stock Down 0.9%

NRx Pharmaceuticals stock traded down $0.02 during trading hours on Friday, hitting $2.10. The stock had a trading volume of 379,991 shares, compared to its average volume of 1,785,069. NRx Pharmaceuticals has a 12-month low of $1.58 and a 12-month high of $3.84. The stock’s 50-day moving average price is $2.31 and its 200-day moving average price is $2.65. The stock has a market capitalization of $62.16 million, a P/E ratio of -0.89 and a beta of 1.62.

NRx Pharmaceuticals (NASDAQ:NRXP) last announced its earnings results on Friday, November 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.07). The company had revenue of $0.24 million for the quarter, compared to the consensus estimate of $6.83 million. On average, research analysts expect that NRx Pharmaceuticals will post -1.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th. Ascendiant Capital Markets restated a “buy” rating and set a $48.00 target price (up previously from $47.00) on shares of NRx Pharmaceuticals in a research report on Friday, January 2nd. Wall Street Zen upgraded shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 23rd. HC Wainwright restated a “buy” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, January 21st. Finally, BTIG Research reissued a “buy” rating and issued a $25.00 price target on shares of NRx Pharmaceuticals in a research note on Thursday, January 15th. Four research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $36.75.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.